Introduction
Several studies have shown that detection of minimal residual disease (MRD) in childhood and adult acute lymphoblastic leukaemia (ALL) is clinically relevant, both in de novo and relapsed ALL as well as in ALL patients undergoing stem cell transplantation. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Consequently, MRD diagnostics is currently incorporated in the stratification for several ALL treatment protocols. 13, 14 In most MRD-based stratification studies, MRD is analyzed by real-time quantitative-polymerase chain reaction (RQ-PCR) analysis of 'leukemia-specific' junctional regions of rearranged immunoglobulin (Ig) genes and T-cell receptor (TCR) genes, which can be considered as 'DNA fingerprints' of the leukemic cells. 15, 16 To ensure comparable MRD results between different MRD-PCR laboratories, standardization and quality control are essential. Based on the experience of the MRD Task Force of the International Berlin-Frankfurt-Mü nster (BFM) Study Group, performing the first pediatric ALL protocol including molecular MRD-based risk group stratification, the standardization is particularly needed for the interpretation of the RQ-PCR data. 17 In fact, guidelines for RQ-PCR data interpretation are not only essential to ensure comparable MRD results between different MRD-PCR laboratories within a single MRD-based treatment protocol, but also to provide a sound basis for the comparison of MRD results between different treatment protocols, including those with new drugs.
The European Study Group on MRD detection in ALL (ESG-MRD-ALL) was established in 2002 and now consists of 30 MRD-PCR laboratories spread across Europe, Israel, Singapore and Australia. The main aims of the ESG-MRD-ALL are the organization of a quality-control program twice per year, the collaborative development and evaluation of new MRD strategies and techniques, and the development of guidelines for the interpretation of RQ-PCR-based MRD data. The guidelines for data interpretation are based on theoretical considerations as well as practical applicability, and include guidelines for: (1) experimental set-up; (2) definition of quantitative range and sensitivity; (3) definition of MRD-positivity and MRDnegativity in follow-up samples; and (4) quantitation of MRD levels in follow-up samples.
Experimental set-up
A standard curve should be made by serially diluting the diagnostic DNA specimen in DNA obtained from mononuclear cells (MNC) from a pool of five to 10 healthy donors. For this purpose, MNC obtained from peripheral blood or bone marrow can be used. Owing to the much easier collection of peripheral blood MNC, most laboratories within the ESG-MRD-ALL use peripheral blood MNC. The serial dilutions should range from 10 À1 to at least 10 À5 (preferably with inclusion of a 5 Â 10
À4
step) and should be tested at least in duplicate. The first dilution step of the diagnostic sample should be based on the blast cell percentage determined in exactly the same sample (e.g. by flow cytometry), so that the 10 À1 dilution really contains 10% blast cells. By plotting the logarithmic value of the dilution against the cycle threshold or crossing point (C T ), a standard curve can be obtained (Figure 1 ). If triplicates are used for the standard curve, all three values should be used, except for obvious technical reasons (e.g. broken capillary). As in most MRD-based protocols a sensitivity p10 À4 is required, the ESG-MRD-ALL recommends the use of 500 ng DNA per reaction.
The threshold of the RQ-PCR assay should always be set in the region of exponential amplification across all amplification plots. This region is depicted in the log view of amplification plots as the portion of the curve that is linear. Often the threshold automatically determined by the instrument software can be used. However, if the threshold appears to be positioned outside the linear part of (some of) the amplification curves, adjustments may be made.
To determine the background of the RQ-PCR assay, that is, the nonspecific amplification of comparable Ig/TCR gene rearrangements present in normal cells, DNA obtained from MNC from a pool of five to 10 healthy donors should be used. As nonspecific amplification is generally only detected at a low level and outside the quantitative range of the RQ-PCR, nonspecific amplification controls should be run at least in X6-fold in each RQ-PCR analysis for each Ig or TCR marker. The lowest C T value of these nonspecific amplification controls is specified as the (highest) background level. In addition, no template controls should always be included at least in duplicate in each RQ-PCR experiment.
Analysis of follow-up samples should be performed in triplicate and all three values should be taken into account.
Definition of the 'quantitative range' and the 'sensitivity'
The sensitivity of an RQ-PCR assay is dependent on several factors, including the type of rearrangement, the size of the junctional region and the amount of DNA in each reaction. [18] [19] [20] If a relatively high proportion of leukemic cells is present, the MRD level can be reliably quantified in the majority of cases. If the level of MRD is very low, the assay becomes less accurate. Thus, the variation in C T values between replicates is generally o1.5, but this increases when the mean C T value of the replicates is high (e.g. C T 436). 15 Within the ESG-MRD-ALL it was therefore, decided to define the quantitative range and the sensitivity. The 'quantitative range' reflects the part of the standard curve in which the MRD levels can be quantified reproducibly and accurately, whereas the 'sensitivity' reflects the lowest MRD level that still can be detected, although not reproducibly and accurately (Figure 1) .
To determine the 'quantitative range' and the 'sensitivity' of the RQ-PCR assay, both the standard curve and the background need to be analyzed. As indicated above, nonspecific amplification is often only detected at a low level and outside the quantitative range of the RQ-PCR. Consequently, an accurate determination of the nonspecific amplification can be difficult. Furthermore, the nonspecific amplification observed in the normal MNC DNA may not be similar to nonspecific amplification present in the follow-up samples of patients as it is well known that follow-up samples can differ significantly in cellular composition, dependent on the follow-up time-point in the protocol. For example, high percentages of T cells can be found during induction therapy, 21 whereas high percentages of precursor B cells can be found post-induction and postmaintenance therapy. 22, 23 Consequently, due to higher frequency of TCR or Ig gene rearrangements, respectively, the nonspecific amplification in follow-up samples may be higher than the generally used nonspecific amplification control (normal peripheral blood MNC DNA). It was decided, therefore, that within the ESG-MRD-ALL the 'quantitative range' should be sufficiently apart from the background, so that cellular composition-related variations in nonspecific amplification would not affect MRD analysis in the 'quantitative range'.
The standard curve of the RQ-PCR assay should theoretically have a slope of -3.3. However, in practice, several patientspecific RQ-PCR assays may perform somewhat less efficiently, resulting in a lower slope. In addition, due to experimental variation, the slope of the standard curve may sometimes be slightly higher than expected. Within the ESG-MRD-ALL, it was, therefore, decided to accept small deviations of the theoretical slope of -3.3.
The quantitative range is defined by the lowest dilution that meets all the following criteria: must give specific amplification, as determined by the shape of the amplification curve and (for the ABI Prism instruments) the multicomponent graph; Guidelines for RQ-PCR MRD data interpretation VHJ van der Velden et al must give reproducible amplification: DC T of all replicates p 1.5; must have all C T values X3.0 lower than the lowest C T value of the background ( ¼ amplification observed in normal MNC DNA); and must have a mean C T value within a defined range from the mean C T value of the previous dilution point: 2.6-4.0 C T between 10-fold dilutions (e.g. 10
À3
-10 À4 ); and 0.5-1.5 C T between two-fold dilutions (e.g. 10 À3 -5 Â 10 À4 ).
The ranges between two dilution points were defined based on theoretical considerations (i.e. 1 C T equals a twofold difference in amount of template) and practical applicability, as determined by analysis of over 1400 RQ-PCR assays. The resulting standard curve, including the lowest dilution of the 'quantitative range' and all previous dilutions: must include at least three dilution points; must have a minimum range of two logs; must have a slope between À3.1 and À3.9; and must have a correlation coefficient X0.98.
If an RQ-PCR does not fulfil the criteria for the 'quantitative range' and resulting standard curve, further analysis should not be performed because of the poor performance of the RQ-PCR.
The sensitivity is the lowest dilution that meets all the following criteria: must give specific amplification, as determined by the shape of the amplification curve and (for the ABI Prism instruments) the multicomponent graph; must have at least one positive replicate; DC T of the replicates is not relevant; must have the lowest C T value X1.0 lower than the lowest C T value of the background ( ¼ amplification observed in normal MNC DNA); must have the lowest C T value o20 cycles from the undiluted sample or, if this undiluted sample is not included in the standard curve, from the intercept of the standard curve (representing the 10 0 dilution).
The 20 cycles in the last criteria reflect five log steps in case of a standard curve with a maximally accepted slope (À3.9). , as this is the lowest dilution X3 C T apart from the lowest C T of the background (C T ¼ 45.5) and the C T value of the replicates p1.5. The mean C T value (33.9) is within 2.6-4.0 from the mean C T value of the 10 À3 dilution (30.5). The resulting standard curve shows a slope of -3.37 and a correlation coefficient of 0.999, both being in the acceptable range. The 'sensitivity' of the assay was defined as 10
À5
, as this is the lowest dilution with the lowest C T value of the replicates X1 apart from the lowest C T of the background (C T ¼ 45.5). Furthermore, the lowest C T value of the 10 À5 dilution (37.1) was within 20 C T from the intercept of the standard curve (20.4).
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The five log steps were chosen because the theoretical sensitivity of an RQ-PCR assay using the recommended DNA input of 500 ng/reaction (corresponding to approximately 1 Â 10 5 cells) is 10
À5 . Both the 'quantitative range' and the 'sensitivity' should be determined based on the results obtained in the RQ-PCR run, in which the follow-up samples are analyzed. Examples of two standard curves and their corresponding 'quantitative range' and 'sensitivity' are shown in Figures 2 and 3 .
It should be noted that the 'quantitative range' of the RQ-PCR assay should be used to determine whether the RQ-PCR assay is sufficiently sensitive (generally p10 À4 ) for reliable quantitative MRD analysis. However, when two Ig/TCR targets are required per patient, some protocols allow the second target to have a smaller 'quantitative range' (e.g. 5 Â 10 À4 ), if the 'sensitivity' is p10 À4 . The required criteria for MRD-PCR targets need to be determined for each MRD-based clinical protocol as the cut-off MRD values for escalation or reduction of treatment can differ between clinical protocols.
Definition of MRD-positivity and MRD-negativity in follow-up samples
The interpretation of RQ-PCR results obtained in follow-up samples is most difficult if MRD levels are outside the 'quantitative range' of the assay. In these cases, it may not always be clear whether the signal observed is due to specific amplification from leukemic cell DNA or from nonspecific amplification of normal DNA. However, the decision to classify a follow-up sample to be 'MRD positive' or 'MRD negative' may have major clinical implications. Therefore, it was decided within the ESG-MRD-ALL to develop separate guidelines for (i) protocols that aim at therapy reduction and (ii) for protocols directed toward therapy intensification.
Clinical protocols that aim at therapy reduction
In studies aiming at therapy reduction, it is particularly important to prevent false-negative MRD results to ensure sufficiently , as this is the lowest dilution X3 C T apart from the lowest C T of the background (C T ¼ 35.7) and the C T value of the replicates p1.5. The mean C T value (31.2) is within 0.5-1.5 from the mean C T value of the 10 À3 dilution (30.2). The resulting standard curve shows a slope of -3.13 and a correlation coefficient of 0.999, both being in the acceptable range. The 'sensitivity' of the assay was defined as 10
À4
, as this is the lowest dilution with the lowest C T value of the replicates X1 apart from the lowest C T of the background (C T ¼ 35.7). Furthermore, the lowest C T value of the 10 À4 dilution (33.2) was within 20 C T from the intercept of the standard curve (20.9).
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intensive treatment for all patients. Therefore, the guidelines are designed in such a way that a follow-up sample can be interpreted as 'MRD positive', even though the C T value is so high that nonspecific amplification cannot be excluded completely.
A sample is considered to be MRD positive if the C T value of at least one of the three replicates is X1.0 C T lower than the lowest C T of background and the C T value of at least one of the three replicates is within 4.0 C T from the highest C T value of the 'sensitivity' (fulfilling all 'sensitivity' criteria).
Consequently, a follow-up sample is considered 'MRD negative', if no amplification is observed at all, if the lowest C T value of the target is within 1 C T from the lowest C T of the background, or if all C T values are more than four cycles separated from the highest C T value of the 'sensitivity'.
Clinical protocols that aim at therapy intensification
In studies aimed at therapy intensification, prevention of falsepositive results is a prerequisite to prevent over-treatment of patients. Therefore, a sample is considered to be 'MRD positive' only if it gives amplification at a level clearly apart from the background.
A sample is considered to be MRD positive if the C T value of at least one of the three replicates is X3.0 C T lower than the lowest C T of background and the C T value of at least one of the three replicates is within 4.0 C T from the highest C T value of the 'sensitivity' (fulfilling all 'sensitivity' criteria).
Logically, very low MRD levels (below the 'quantitative range') should always be judged with caution, especially if only one well of the three replicates is positive. In such case, re-analysis of the doubtful sample(s) may be performed, but one should be aware that by definition the results will often not be reproducible.
Examples of MRD data interpretation of follow-up samples are shown in Figures 4 and 5 .
Quantitation of MRD levels in follow-up samples
Although RQ-PCR is in principle a quantitative technique, it does not mean that the data obtained can be quantified in each case. Within the ESG-MRD-ALL, it was decided that data can only be quantified if the MRD level is within the 'quantitative range'. Outside that range, data are no longer fully reproducible and therefore, cannot be quantified accurately.
Furthermore, in order to obtain accurate MRD data, the RQ-PCR data obtained for the Ig/TCR gene rearrangements should À4 ; this resulted in a standard curve with a slope of -3.50, a correlation coefficient of 1.000 and an intercept of 19.8. The 'sensitivity' of the assay was also 10
À4
, as both C T values of the 10 À5 dilution (42.2; 36.4) were within one C T value from the lowest C T value of the background (37.3). The highest C T value of the 'sensitivity' was 34.0; the lowest C T value of the background was 37.3. Follow-up sample 1 shows amplification in all three wells, the mean C T value (31.1) being lower than the highest C T value of the 'quantitative range' (34.0). This sample is considered MRD positive and the MRD level can accurately be determined using the standard curve of the assay, resulting in an MRD level of 6 Â 10 À4 . Follow-up sample 2 shows amplification below the 'quantitative range' in all three wells, two C T values (35.5; 35.4) being X1 C T from the lowest C T value of the background. This sample therefore is considered MRD positive, but accurate quantitation is not possible. Consequently, this sample is considered 'MRD positive, o10
'. Follow-up sample 3 shows amplification in all three wells, but all C T values are within 1 C T from the lowest C T value of the background, and therefore, this sample is considered MRD negative.
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VHJ van der Velden et al be corrected for the amount and 'amplifiability' of the DNA of the diagnosis sample and the follow-up samples. This should be done by analyzing a control gene in parallel to the Ig or TCR gene target. If the RQ-PCR of the control gene shows a lower amount of template than expected based on physical measurements (e.g. optical density measurement), special caution is needed as this lower value can be the result of inhibition, which can be found in a substantial number of bone marrow or peripheral blood samples (5-10%). 24 Addition of bovine serum albumin (BSA) prevents inhibition 24 ).
For samples that cannot be quantified, the quality/quantity of the DNA should always be checked by RQ-PCR analysis of the control gene. These control-gene data should be within the predefined acceptable range, but are not used for correcting the MRD level. All MRD data (either quantitative, positive but not quantifiable or negative) should always be reported together with the 'quantitative range' and the 'sensitivity' of the assay.
Examples of MRD data reporting of follow-up samples are shown in Figures 4 and 5 . ; this resulted in a standard curve with a slope of -3.17, a correlation coefficient of 1.000 and an intercept of 21.1. The 'sensitivity' of the assay was 10
À5
. The highest C T value of the 'sensitivity' was 35.7; the lowest C T value of the background was 43.9. Follow-up sample 1 shows amplification in all three wells, all C T values (36.6, 37.1 and 36.5) being o4 apart from the highest C T value of the 'sensitivity' (35.7) and more than 1 C T apart from the lowest C T value of the background (43.9). This sample is considered MRD positive. As the mean C T value of this sample (36.7) is higher than the highest C T value of the 'quantitative range' (34.0), the exact MRD level cannot be defined accurately; the sample is therefore, considered 'MRD positive, o10
À4
'. Follow-up sample 2 shows amplification in one out of three wells only, with a C T value of 40.9. This value is more than 4 C T apart from the highest C T value of the 'sensitivity' (35.7), and consequently this sample is considered MRD negative. Follow-up sample 3 shows no specific amplification at all, and is considered MRD negative.
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Conclusions
The guidelines for RQ-PCR MRD data interpretation presented here can be used in all MRD studies that employ Ig/TCR gene rearrangements as MRD-PCR target. Their application is relatively simple and enables highly comparable interpretation of MRD data between different MRD laboratories, as determined in several quality control rounds performed within the ESG-MRD-ALL (manuscript in preparation). Logically, in some exceptional cases, interpretation of RQ-PCR data may not be appropriate using the ESG-MRD-ALL guidelines; in such cases one can deviate from these guidelines as long as this is clearly reported.
The application of the ESG-MRD-ALL guidelines will ensure uniform data interpretation in different MRD-PCR laboratories within the same MRD-based clinical protocol. Furthermore, the ESG-MRD-ALL guidelines will also facilitate the comparison of levels of residual disease achieved by different treatment protocols, including those with new drugs. Indeed, the ESG-MRD-ALL guidelines are already being utilized in several related MRD intervention clinical trials, which use the same induction regimen and identical MRD-based stratification, followed by treatment arms that differ per protocol.
